Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH

NCT00116844 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00116844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00116844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
March 29, 2005
Completion date
January 10, 2006
Enrollment
73 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

infections, herpesviridae